Get started
Ligand Pharmaceuticals IncorporatedLigand Pharmaceuticals IncorporatedLigand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LGND chart


Full chart

LGND upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.11 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
44.39
Basic EPS (TTM)
2.63 USD
Net income (FY)
‪52.15 M‬ USD
Revenue (FY)
‪131.31 M‬ USD
Shares float
‪18.46 M‬
Beta (1Y)
1.23

Employees


Employees (FY)
58
Change (1Y)
−18 −23.68%
Revenue / Employee (1Y)
‪2.26 M‬ USD
Net income / Employee (1Y)
‪927.91 K‬ USD

About Ligand Pharmaceuticals Incorporated


Sector
Health Technology
CEO
Todd C. Davis
Headquarters
Jupiter
Website
ligand.com
Founded
1987
FIGI
BBG000BKF014
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

LGND news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LGND is 116.55 USD — it has decreased by −0.21% in the past 24 hours. Watch Ligand Pharmaceuticals Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ligand Pharmaceuticals Incorporated stocks are traded under the ticker LGND.
LGND stock has fallen by −8.56% compared to the previous week, the month change is a 4.43% rise, over the last year Ligand Pharmaceuticals Incorporated has showed a 97.07% increase.
We've gathered analysts' opinions on Ligand Pharmaceuticals Incorporated future price: according to them, LGND price has a max estimate of 157.00 USD and a min estimate of 125.00 USD. Watch LGND chart and read a more detailed Ligand Pharmaceuticals Incorporated stock forecast: see what analysts think of Ligand Pharmaceuticals Incorporated and suggest that you do with its stocks.
LGND reached its all-time high on Oct 1, 2018 with the price of 278.62 USD, and its all-time low was 6.60 USD and was reached on Oct 28, 2008. View more price dynamics on LGND chart.
See other stocks reaching their highest and lowest prices.
LGND stock is 5.86% volatile and has beta coefficient of 1.23. Track Ligand Pharmaceuticals Incorporated stock price on the chart and check out the list of the most volatile stocks — is Ligand Pharmaceuticals Incorporated there?
Today Ligand Pharmaceuticals Incorporated has the market capitalization of ‪2.11 B‬, it has decreased by −3.37% over the last week.
Yes, you can track Ligand Pharmaceuticals Incorporated financials in yearly and quarterly reports right on TradingView.
Ligand Pharmaceuticals Incorporated is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
LGND earnings for the last quarter are 1.84 USD per share, whereas the estimation was 1.35 USD resulting in a 36.59% surprise. The estimated earnings for the next quarter are 1.18 USD per share. See more details about Ligand Pharmaceuticals Incorporated earnings.
Ligand Pharmaceuticals Incorporated revenue for the last quarter amounts to ‪51.81 M‬ USD, despite the estimated figure of ‪40.60 M‬ USD. In the next quarter, revenue is expected to reach ‪39.02 M‬ USD.
LGND net income for the last quarter is ‪−7.17 M‬ USD, while the quarter before that showed ‪−51.91 M‬ USD of net income which accounts for 86.18% change. Track more Ligand Pharmaceuticals Incorporated financial stats to get the full picture.
No, LGND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 58.00 employees. See our rating of the largest employees — is Ligand Pharmaceuticals Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ligand Pharmaceuticals Incorporated EBITDA is ‪55.57 M‬ USD, and current EBITDA margin is 35.97%. See more stats in Ligand Pharmaceuticals Incorporated financial statements.
Like other stocks, LGND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ligand Pharmaceuticals Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ligand Pharmaceuticals Incorporated technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ligand Pharmaceuticals Incorporated stock shows the strong buy signal. See more of Ligand Pharmaceuticals Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.